The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial
NCT03158935
Completed
This is a phase 1b study for patients with metastatic (cancer has spread to various parts of the body) melanoma and ovarian cancer. The main purpose is to examine the safety and efficacy of administering pembrolizumab after receiving chemotherapy, tumor-infiltrating lymphocytes (TIL) and low dose interleukin 2 (IL-2). Patients will first receive either cyclophosphamide, or cyclophosphamide and fludarabine. These are chemotherapy agents that prepare the body to receive TILs. Patients are then i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2020
Locations: Princess Margaret Cancer Centre, Toronto, Ontario
Conditions: Advanced Ovarian Cancer, Malignant Melanoma
Register for Updates
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL
NCT02055820
Completed
This is a multicenter, open-label, dose-finding study of venetoclax administered orally in combination with rituximab (R) or obinutuzumab (G) and standard doses of cyclophosphamide, doxorubicin, vincristine and oral prednisone (CHOP) in participants with Non-Hodgkin's Lymphoma (NHL). The study consisted of 2 stages: a dose-finding Phase Ib stage and a Phase II expansion stage. In the Phase I portion of the study, participants were randomized to one of 2 treatment arms venetoclax in combination w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/26/2020
Locations: St. Jude Heritage Healthcare, Fullerton, California +51 locations
Conditions: Lymphoma, Non-Hodgkin
Register for Updates
Combination Chemotherapy in Treating Patients With Breast Cancer
NCT00003088
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs at different times or combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy consisting of either doxorubicin, cyclophosphamide, or paclitaxel given at different times with that of combination chemoth... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/28/2020
Locations: CCOP - Scottsdale Oncology Program, Scottsdale, Arizona +18 locations
Conditions: Breast Cancer
Register for Updates
Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL
NCT00041288
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy. Sometimes the transplanted cells are rejected by the body's normal tissues. Cyclosporine, mycophenolate mofetil, methotrexate, and tacrolimus may prevent this from happening. PURPOSE:... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/08/2020
Locations: Rocky Mountain Cancer Centers, Denver, Colorado +22 locations
Conditions: Leukemia, Lymphoma
Register for Updates
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia
NCT00553202
Completed
RATIONALE: Giving chemotherapy before a donor stem cell transplant using stem cells that closely match the patient's stem cells, helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Givi... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
04/07/2020
Locations: UAB Comprehensive Cancer Center, Birmingham, Alabama +51 locations
Conditions: Leukemia
Register for Updates
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00720109
Completed
This phase II/III trial is studying the side effects and how well giving dasatinib together with combination chemotherapy works in treating young patients with newly diagnosed acute lymphoblastic leukemia (ALL). Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving dasatinib together with combin... Read More
Gender:
ALL
Ages:
Between 2 years and 30 years
Trial Updated:
04/04/2020
Locations: Children's Hospital of Alabama, Birmingham, Alabama +133 locations
Conditions: Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Register for Updates
Tamoxifen in Treating Women With High-Risk Breast Cancer
NCT00002542
Completed
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. Chemotherapy uses different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase III trial to study the effectiveness of tamoxifen following surgery and chemotherapy in treating women who have stage I breast cancer at high risk of recurrence or stage II or stage III breast cancer.
Gender:
FEMALE
Ages:
120 years and below
Trial Updated:
03/30/2020
Locations: Dr. H. Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador +47 locations
Conditions: Breast Cancer
Register for Updates
High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer
NCT00003032
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known whether standard therapy is more effective than high dose chemotherapy for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of high dose chemotherapy plus peripheral stem c... Read More
Gender:
FEMALE
Ages:
Between 16 years and 60 years
Trial Updated:
03/30/2020
Locations: Tom Baker Cancer Center - Calgary, Calgary, Alberta +24 locations
Conditions: Breast Cancer
Register for Updates
High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma
NCT00354744
Completed
RATIONALE: Drugs used in chemotherapy, such as vincristine, irinotecan, ifosfamide, etoposide, doxorubicin, cyclophosphamide, and dactinomycin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving high-dose combination chemotherapy together with radiation therapy may kill more tumor cells. PURPOSE: This phase III trial is studying how well giving high-dose co... Read More
Gender:
ALL
Ages:
49 years and below
Trial Updated:
01/15/2020
Locations: Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama +165 locations
Conditions: Sarcoma
Register for Updates
Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma
NCT01883323
Completed
This is a phase II clinical study for patients with metastatic (the cancer has spread to other parts of the body) melanoma. Patients will receive an infusion (given by vein) of autologous tumor infiltrating lymphocytes (TILs). TILs are a type of white blood cells that recognizes tumor cells and enter them which causes the tumor cells to break down. Prior to the cell infusion, patients will receive a two drugs cyclophosphamide and fludarabine to prepare the body to receive the TILs. After cell i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/07/2019
Locations: Princess Margaret Cancer Centre, Toronto, Ontario
Conditions: Metastatic, Stage III or Stage IV, Melanoma
Register for Updates
Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
NCT01492673
Completed
The purpose of this study is to find out what effects, good and/or bad treatment with a new combination of drugs, cyclophosphamide, topotecan, and bevacizumab has on the patient and their cancer. The medications, cyclophosphamide and topotecan, are standard drugs often used together for the treatment of cancer in children with either Ewing's sarcoma or neuroblastoma. Bevacizumab is an experimental drug called an antibody that targets a protein important in the growth of cancer cells called vas... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
10/28/2019
Locations: Phoenix Children'S Hospital, Phoenix, Arizona +6 locations
Conditions: Neuroblastoma, Sarcoma
Register for Updates
A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia
NCT01905943
Completed
This multicenter, open-label, single-arm study will evaluate the safety and efficacy of obinutuzumab alone or in combination with chemotherapy in participants with previously untreated or relapsed/refractory chronic lymphocytic leukemia (CLL). This is a Post-Authorization Safety Study. Participants will receive 6 cycles of single-agent obinutuzumab or obinutuzumab in combination with chemotherapy at the investigator's discretion. Each participant will be followed until 30 months after the last p... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2019
Locations: Hospital Iturraspe, Santa Fé, Not set +173 locations
Conditions: Chronic Lymphocytic Leukemia
Register for Updates